Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease.

abstract：:Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the ther...

journal_title：Current pharmaceutical design

authors： Lim KH,Baek KH

更新日期：2013-01-01 00:00:00

abstract：:Dioxygen (O2) is an exogenously supplied gas with a number of properties that make it valuable as a biological source of energy and as a result much of life has become dependent on this molecule. Nitric oxide (NO), carbon dioxide (CO) and hydrogen sulfide (H2S) are small molecules that are sometimes in a gaseous state...

journal_title：Current pharmaceutical design

authors： Fukuto JM,Collins MD

更新日期：2007-01-01 00:00:00

abstract：:Urological cancer refers to cancer in organs of the urinary system and the male reproductive system. It mainly includes prostate cancer, bladder cancer, renal cancer, etc., seriously threatening patients' survival. Although there are many advances in the treatment of urological cancer, approved targeted therapies ofte...

journal_title：Current pharmaceutical design

authors： Liu Q,Gu J,Zhang E,He L,Yuan ZX

更新日期：2020-01-01 00:00:00

abstract：:Atherosclerosis is an inflammatory vascular disease that is characterized by progressive accumulation of cholesterol in the arterial walls and it is a major cause of cardiovascular disease. Issues related to the side effects of synthetic drugs have in recent times, led to the misuse of drugs, a lack of patient consult...

journal_title：Current pharmaceutical design

authors： Gholipour S,Sewell RDE,Lorigooini Z,Rafieian-Kopaei M

更新日期：2018-01-01 00:00:00

abstract：BACKGROUNDS:Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological ...

journal_title：Current pharmaceutical design

authors： Wang L,Yu X,Zhang C,Zeng T

更新日期：2018-01-01 00:00:00

abstract：:The final aim/target of Pharmaceutical Sciences is to design successful dosage forms for effective therapy, considering individual patient needs and compliance. Development of new drug entities, particularly using peptides and proteins, is growing in importance and attracting increased interest, as they are specifical...

journal_title：Current pharmaceutical design

authors： Degim IT,Celebi N

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:The population with autism spectrum disorder (ASD) has been increasing and is currently estimated to be 1 in 58 births. The increased prevalence of ASD together with the lack of knowledge on the processes of aging in this population, the support needed at this stage of life, and the associated risk factors, ...

journal_title：Current pharmaceutical design

authors： Ruggieri V,Gómez JLC,Martínez MM,Arberas C

更新日期：2019-01-01 00:00:00

abstract：:Despite the significant progresses made in antiretroviral therapy, current drugs still cannot cure or prevent HIV infection. And all drugs continue to select for drug-resistant HIV strains. Consequently, new antiretroviral drugs are constantly being developed. To ensure safety, these drugs are usually designed to inhi...

journal_title：Current pharmaceutical design

authors： Provencher VM,Coccaro E,Lacasse JJ,Schang LM

更新日期：2004-01-01 00:00:00

abstract：:CHD is one of the most common serious chronic conditions in postmenopausal women and leads to extremely high risk for recurrent myocardial infarction and death. On the basis of the currently available randomized clinical-trial results the role of conventional HRT for treatment and prevention of CHD is rapidly evolving...

journal_title：Current pharmaceutical design

authors： Francucci CM,Camilletti A,Boscaro M

更新日期：2005-01-01 00:00:00

abstract：:Supraventricular tachycardias (SVTs) are observed in 0,1-0,4% of the paediatric population and represent an important clinical problem with related significant health and social issues. Most tachycardias are paroxysmal, being associated with sudden onset and termination, and only a relatively small number of them is p...

journal_title：Current pharmaceutical design

authors： Calabrò MP,Cerrito M,Luzza F,Oreto G

更新日期：2008-01-01 00:00:00

abstract：:Biodegradable particles have important applications in Drug Delivery Systems (DDS) of protein/peptide drugs. And recently, particle systems have also showed to be powerful for vaccine delivery (adjuvant) in order to solve the difficulties when conventional Alum adjuvant was used. However, in above applications, the pr...

journal_title：Current pharmaceutical design

authors： Wang L,Yang T,Ma G

更新日期：2015-01-01 00:00:00

abstract：:Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing conditions resulting from immune system activity in a genetically predisposed individual. IBD is based on progressive damage to the inflamed gut tissue. As its pathogenesis remains unknown, recent accumu...

journal_title：Current pharmaceutical design

authors： Alimohammadi N,Koosha F,Rafeian-Kopaei M

更新日期：2020-01-01 00:00:00

abstract：:Drug development for neurodegenerative diseases such as Alzheimer's disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developi...

journal_title：Current pharmaceutical design

authors： Gomes B,Loureiro JA,Coelho MA,Pereira Mdo C

更新日期：2015-01-01 00:00:00

abstract：:Polyunsaturated fatty acids (PUFA) are a family of lipids including some subgroups identified by the position of the last double bond in their structure. PUFA n-3 include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while PUFA n-6 include linoleic acid (LA) and arachidonic a...

journal_title：Current pharmaceutical design

authors： Zuliani G,Galvani M,Leitersdorf E,Volpato S,Cavalieri M,Fellin R

更新日期：2009-01-01 00:00:00

abstract：:Aspirin is the cornerstone of treatment in patients with coronary artery disease. However, several studies investigating the in vitro response of platelets to the administration of aspirin showed this response to be variable, with some patients exhibiting non-responsiveness or resistance. Aspirin resistance may be cat...

journal_title：Current pharmaceutical design

authors： Papathanasiou A,Goudevenos J,Tselepis AD

更新日期：2009-01-01 00:00:00

abstract：:Manufacturing of pharmaceutical solids involves different unit operations and processing steps such as powder blending, fluidization, sieving, powder coating, pneumatic conveying and spray drying. During these operations, particles come in contact with other particles, different metallic, glass or polymer surfaces and...

journal_title：Current pharmaceutical design

authors： Desai PM,Tan BM,Liew CV,Chan LW,Heng PW

更新日期：2015-01-01 00:00:00

abstract：:The number of protein 3D structures without function annotation in Protein Data Bank (PDB) has been steadily increased. Many of these proteins are relevant for Pharmaceutical Design because they may be enzymes of different classes that could become drug targets. This fact has led in turn to an increment of demand for ...

journal_title：Current pharmaceutical design

authors： Concu R,Podda G,Ubeira FM,González-Díaz H

更新日期：2010-01-01 00:00:00

abstract：:Methicillin-resistant Staphylococcus aureus (MRSA) remains the single biggest challenge in infectious disease in the civilized world. Moreover, vancomycin resistance is also spreading, leading to fears of untreatable infections as were common in ancient times. Molecular microbiology and bioinformatics have revealed ma...

journal_title：Current pharmaceutical design

authors： Magana M,Ioannidis A,Magiorkinis E,Ursu O,Bologa CG,Chatzipanagiotou S,Hamblin MR,Tegos GP

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Erectile dysfunction (ED) is an evolving health problem in the aging male population. Chronic low-grade inflammation is a critical component of ED pathogenesis and a probable intermediate stage of endothelial dysfunction, especially in metabolic diseases, with the inclusion of obesity, metabolic syndrome, an...

journal_title：Current pharmaceutical design

authors： Kaya-Sezginer E,Gur S

更新日期：2020-01-01 00:00:00

abstract：:Marine plants, animals and microorganisms display steady growth in the ocean and are abundant carbohydrate resources. Specifically, natural polysaccharides obtained from brown algae have been drawing increasing attention owing to their great potential in pharmaceutical applications. This review describes the structura...

journal_title：Current pharmaceutical design

authors： Li J,Cai C,Yang C,Li J,Sun T,Yu G

更新日期：2019-01-01 00:00:00

abstract：:Telomerase is a specialized enzymatic complex responsible for the synthesis of telomeric repeats 5'-TTAGGG-3' localized at the ends of eukaryotic chromosomes. This mechanism prevents shortening of telomeres after each cell division. The enzyme is detected in about 85% of human tumors, but it is not expressed in normal...

journal_title：Current pharmaceutical design

authors： Romaniuk A,Kopczynski P,Ksiazek K,Rubis B

更新日期：2014-01-01 00:00:00

abstract：:Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a non-flavonoid polyphenol that may be present in a limited number of foodstuffs such as grapes and red wine. Resveratrol has been reported to exert a plethora of health benefits through many different mechanisms of action. This versatility and presence in the human di...

journal_title：Current pharmaceutical design

authors： Tomé-Carneiro J,Larrosa M,González-Sarrías A,Tomás-Barberán FA,García-Conesa MT,Espín JC

更新日期：2013-01-01 00:00:00

abstract：:Myocarditis is a disease whose pathogenesis is not completely understood and whose prevalence is likely underestimated. Individuals afflicted with this condition may be treated with agents that relieve symptoms arising from inflammation and concurrent cellular damage. One class of drugs commonly used in the treatment ...

journal_title：Current pharmaceutical design

authors： Godsel LM,Leon JS,Engman DM

更新日期：2003-01-01 00:00:00

abstract：:A new controlled delivery system has been developed for ropinirole (RP) for the treatment of Parkinson´s Disease (PD) consisting in PLGA microparticles (MPs) which exhibited in vitro constant release of RP (78.23 µg/day/10 mg MPs) for 19 days. The neuroprotective effects of RP released from MPs were evaluated in SKN-A...

journal_title：Current pharmaceutical design

authors： Negro S,Boeva L,Slowing K,Fernandez-Carballido A,Garcia-García L,Barcia E

更新日期：2017-01-01 00:00:00

abstract：:The complete DNA sequence of the human genome and of several related mammals are now available, due to the investments of enormous resources and advances in sequencing technology. Novel technologies have been developed to compare multiple genomes with each other, thus specifying regions of sequence similarity among ma...

journal_title：Current pharmaceutical design

authors： Möller S,Zettl UK,Serrano-Fernández P,Goertsches R

更新日期：2006-01-01 00:00:00

abstract：:MNPs find numerous important biomedical applications owing to their high biocompatibility and unique magnetic properties at the bottom level. Among several other biomedical applications, MNPs are gaining importance in treating various kinds of cancer either as a hyperthermia agent alone or as a drug/gene carrier for s...

journal_title：Current pharmaceutical design

authors： T S A,Shalumon KT,Chen JP

更新日期：2019-01-01 00:00:00

abstract：:Syncytin-1 is a protein coded by a human endogenous retrovirus (HERV) gene of the HERV-W family (HERVWE1). Syncytin- 1 mediates formation of syncytiotrophoblasts through fusion of cytotrophoblasts, a hallmark of terminal differentiation of placental trophoblast linage. Syncytin-1 also possesses nonfusogenic functions ...

journal_title：Current pharmaceutical design

authors： Zhuang XW,Li J,Brost BC,Xia XY,Chen HB,Wang CX,Jiang SW

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Type 1 diabetes is a chronic autoimmune disease featured by insulin deprivation caused by pancreatic β-cell loss, followed by hyperglycaemia. OBJECTIVE:Currently, there is no cure for this disease in clinical treatment, and patients have to accept a lifelong injection of insulin. The exploration of potentia...

journal_title：Current pharmaceutical design

authors： Wang R,Zhou Y,Zhang Y,Li S,Pan R,Zhao Y

更新日期：2020-12-17 00:00:00

abstract：BACKGROUND:Neglected tropical diseases (NTDs) represent a serious problem in a number of countries around the world and especially in Africa and South America, affecting mostly the poor population which has limited access to the healthcare system. The drugs currently used for the treatment of NTDs are dated many decade...

journal_title：Current pharmaceutical design

authors： Chazapi E,Magoulas GE,Prousis KC,Calogeropoulou T

更新日期：2020-12-09 00:00:00

abstract：:Gene therapy may be capable of treating a variety of diseases, a prerequisite of which is the successful delivery of polynucleic acids (e.g., DNA, RNA) to a patient's cells. Delivery can be achieved technologically (e.g., using electroporation), using viruses (natural gene delivery vectors) or non-viral vectors (e.g.,...

journal_title：Current pharmaceutical design

authors： Clancy KFA,Hardy JG

更新日期：2017-01-01 00:00:00